September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Investigating Maspin Expression in Ocular Surface Squamous Neoplasia

Author Affiliations & Notes
  • Silvin Bakalian
    McGill University, Montreal, Quebec, Canada
  • Pablo Zoroquiain
    McGill University, Montreal, Quebec, Canada
  • Ana Beatriz Toledo Dias
    McGill University, Montreal, Quebec, Canada
  • Dina Abdulmannan
    McGill University, Montreal, Quebec, Canada
  • Patrick Logan
    McGill University, Montreal, Quebec, Canada
  • Miguel N Burnier
    McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Silvin Bakalian, None; Pablo Zoroquiain, None; Ana Beatriz Dias, None; Dina Abdulmannan, None; Patrick Logan, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2411. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Silvin Bakalian, Pablo Zoroquiain, Ana Beatriz Toledo Dias, Dina Abdulmannan, Patrick Logan, Miguel N Burnier; Investigating Maspin Expression in Ocular Surface Squamous Neoplasia

      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):2411.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Maspin is a protein that belongs to the serine protease superfamily. Several studies have shown controversial results with respect to Maspin expression in cancer. For instance, it is down regulated in some tumors, while it is overexpressed in others, suggesting that maspin may play a diverse role in different cancers. The aim of this study is to evaluate the immunoexpression of maspin in ocular surface squamous neoplasia (OSSN), including conjunctival intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC).

Methods : A total of 48 OSSN cases were evaluated for maspin expression using an automated immunohistochemistry process. The OSSN cases included 21 CIN I, 9 CIN II, 6 CIN III, and 12 SCC cases. Nine cases of normal conjunctiva were used as controls. Immunohistochemical expression was assessed based on the intensity and extension of the staining. Intensity was assessed as follows: 0=none, 1=weak, 2=moderate, and 3=strong. Extent was evaluated as the percentage of cells with positive staining (0=none, 1=≤50%, 2=51%-75%, and 3=≥76% of cells). A score ranging between 0-6 was achieved by adding these two semi-quantitative staining parameters. Cases were grouped into two different immunostaining categories: Low immunostaining=score 0-4 and high immunostaining=score 5-6.

Results : Maspin immunostaining was negative in all control cases of normal conjunctiva and different positive staining levels were found within OSSN group (P=0.04). Furthermore, 19% of CIN I was negative for maspin, while CIN II, CIN III and SCC were all positive. Significantly higher immunostaining levels were detected in SCC compared to CIN I and CIN II (P=0.03). However, no differences were noticed between CIN III and SCC (P=0.5). A direct correlation was found between tumor grade and increased levels of maspin immunostaining (R2=0.64, P=<0.0001).

Conclusions : Maspin expression increases as cells progress from benign to malignant across the OSSN spectrum. To the best of our knowledge, this is the first study investigating maspin expression in OSSN. Maspin may play an important role in the pathological transformation of CIN into SCC. Further molecular studies are needed to elucidate the exact mechanism underlying the relationship between maspin and OSSN.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×